Personalising sarcoma care using quantitative multimodality imaging for response assessment

Clin Radiol. 2021 Apr;76(4):313.e1-313.e13. doi: 10.1016/j.crad.2020.12.009. Epub 2021 Jan 19.

Abstract

Over the last decades, technological developments in the field of radiology have resulted in a widespread use of imaging for personalising medicine in oncology, including patients with a sarcoma. New scanner hardware, imaging protocols, image reconstruction algorithms, radiotracers, and contrast media, enabled the assessment of the physical and biological properties of tumours associated with response to treatment. In this context, medical imaging has the potential to select sarcoma patients who do not benefit from (neo-)adjuvant treatment and facilitate treatment adaptation. Due to the biological heterogeneity in sarcomas, the challenge at hand is to acquire a practicable set of imaging features for specific sarcoma subtypes, allowing response assessment. This review provides a comprehensive overview of available clinical data on imaging-based response monitoring in sarcoma patients and future research directions. Eventually, it is expected that imaging-based response monitoring will help to achieve successful modification of (neo)adjuvant treatments and improve clinical care for these patients.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Cell Proliferation
  • Fibroblasts / pathology
  • Glucose / metabolism
  • Humans
  • Hypoxia / pathology
  • Multimodal Imaging*
  • Neoadjuvant Therapy
  • Neoplasm Metastasis
  • Patient Care Planning*
  • Precision Medicine*
  • Sarcoma / blood supply
  • Sarcoma / diagnostic imaging*
  • Sarcoma / pathology
  • Sarcoma / therapy*

Substances

  • Biomarkers
  • Glucose